Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REGN

Regeneron Pharmaceuticals, Inc

Jun 17 • 04:00PM ET

508.86

Dollar change -13.82
Percentage change -2.64	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ SPY IVV VTV XLV IBB JEPI COWZ

Scroll to Statements

Index	NDX, S&P 500	P/E	12.95	EPS (ttm)	39.29	Insider Own	3.61%	Shs Outstand	106.40M	Perf Week	-2.80%
Market Cap	54.94B	Forward P/E	12.85	EPS next Y	39.59	Insider Trans	0.00%	Shs Float	104.06M	Perf Month	-14.38%
Income	4.50B	PEG	9.52	EPS next Q	8.57	Inst Own	87.17%	Short Float	2.59%	Perf Quarter	-23.48%
Sales	14.09B	P/S	3.90	EPS this Y	-21.68%	Inst Trans	0.98%	Short Ratio	2.04	Perf Half Y	-31.33%
Book/sh	271.60	P/B	1.87	EPS next Y	10.80%	ROA	12.51%	Short Interest	2.70M	Perf Year	-50.43%
Cash/sh	77.33	P/C	6.58	EPS next 5Y	1.36%	ROE	15.96%	52W Range	476.49 - 1211.20	Perf YTD	-28.56%
Dividend Est.	2.83 (0.56%)	P/FCF	17.71	EPS past 5Y	15.74%	ROIC	14.02%	52W High	-57.99%	Beta	0.31
Dividend TTM	1.76 (0.35%)	Quick Ratio	4.03	Sales past 5Y	16.71%	Gross Margin	82.28%	52W Low	6.79%	ATR (14)	20.93
Dividend Ex-Date	May 20, 2025	Current Ratio	4.93	EPS Y/Y TTM	15.65%	Oper. Margin	28.11%	RSI (14)	40.52	Volatility	1.84% 5.15%
Employees	15106	Debt/Eq	0.09	Sales Y/Y TTM	7.52%	Profit Margin	31.94%	Recom	1.67	Target Price	726.00
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	15.94%	Payout	0.00%	Rel Volume	0.67	Prev Close	522.68
Sales Surprise	-6.74%	EPS Surprise	-4.66%	Sales Q/Q	-3.70%	Earnings	Apr 29 BMO	Avg Volume	1.32M	Price	508.86
SMA20	-5.57%	SMA50	-9.24%	SMA200	-32.25%	Trades		Volume	889,813	Change	-2.64%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976
Mar-24-23	Upgrade	Jefferies	Hold → Buy	$675 → $925
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform

Show Previous Ratings

Today 07:14AM	Anne Wojcicki wins bid to buy back 23andMe for $305M (MedTech Dive)
05:44AM	FDA clears CSLs swelling disease drug; Regeneron loses 23andMe auction (BioPharma Dive)
04:00AM	Anne Wojcicki's bid to buy back 23andMe may not end legal fight over DNA customer data (Yahoo Finance)
04:00AM	Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data (Yahoo Finance)
Jun-16-25 05:22PM	Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer (Reuters)
01:24PM	Loading…
01:24PM	Squawk Pod: CBO Fact vs Fiction; A New Middle East - 06/16/25 Audio Only (CNBC TV)
07:23AM	Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron (CNBC TV)
06:36AM	EHA 2025: Regenerons Lynozyfic with Amgens Kyprolis combo emerges for R/R MM (Pharmaceutical Technology)
Jun-15-25 11:21AM	Dupixent (dupilumab) Demonstrated Superiority Over Xolair (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial (GlobeNewswire)
09:59AM	These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025 (Motley Fool)
05:38AM	Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis (Insider Monkey)
Jun-14-25 05:46PM	Anne Wojcickis nonprofit wins bid to acquire genetic testing company 23andMe (CNN Business)
09:55AM	Anne Wojcickis nonprofit reaches deal to acquire 23andMe (TechCrunch)
Jun-13-25 04:30PM	23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm (Reuters)
04:22PM	23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process (GlobeNewswire)
04:14PM	Loading…
04:14PM	Anne Wojcicki Wins Bidding for 23andMe (The Wall Street Journal)
08:57AM	These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025 (Motley Fool)
Jun-12-25 07:00PM	Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch (Yahoo Finance Video)
12:25PM	Dozens of states sue to block the sale of 23andMes genetic data after its former CEO pushes the purchase price $50 million higher (Fortune)
11:05AM	Is This Stock a Buy After Acquiring a Potential Zepbound Competitor? (Motley Fool)
10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
Jun-11-25 08:01PM	JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target (Insider Monkey)
02:01PM	Squawk Pod: Regeneron CEO on 23andme & $275m in Margaritaville - 06/11/25 Audio Only (CNBC TV)
10:10AM	23andMe says 15% of customers asked to delete their genetic data since bankruptcy (TechCrunch)
09:10AM	Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research (CNBC TV)
Jun-10-25 02:56PM	Rep. James Comer on 23andMe bankruptcy and data privacy (CNBC TV)
11:24AM	27 states seek to block 23andMe from selling DNA info, citing privacy concerns (Quartz)
04:23AM	Stock Market News for Jun 10, 2025 (Zacks)
Jun-09-25 11:35PM	States sue to block sale of 23andMe's personal genetic data without customer consent (MarketWatch)
11:00AM	Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season (Benzinga)
10:30AM	Loading…
10:30AM	Regeneron and Sanofis dupilumab shows promise in AD trial (Clinical Trials Arena)
08:44AM	Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space (Zacks)
06:00AM	As tech leads, which stocks have outperformed since April 8 rout? (Yahoo Finance Video)
Jun-07-25 06:30PM	Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color (GlobeNewswire)
Jun-06-25 01:27PM	Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory (Insider Monkey)
09:12AM	Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise? (Zacks)
Jun-05-25 04:16PM	Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial (Barrons.com)
04:06PM	The New Twist In Regeneron's 23andMe Bankruptcy Buyout (Investor's Business Daily)
10:18AM	23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer (Investor's Business Daily)
08:45AM	REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock? (Zacks)
Jun-04-25 09:41PM	23andMes Former CEO Pushes Purchase Price Nearly $50 Million Higher (The Wall Street Journal)
07:13PM	23andMe seeks new bids after $305 million offer from its co-founder (Reuters)
05:16AM	Regeneron makes obesity push; Atai, Alto ink brain drug deals (BioPharma Dive)
Jun-03-25 08:18PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
09:05AM	Regeneron price target lowered to $600 from $800 at BMO Capital (TipRanks)
04:52AM	Regeneron to acquire rights for Hansohs HS-20094 therapy (Pharmaceutical Technology)
Jun-02-25 10:29AM	Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response (Benzinga)
07:56AM	ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles (Pharmaceutical Technology)
07:45AM	The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip (Motley Fool)
07:44AM	Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster. (Barrons.com)
07:05AM	Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist (GlobeNewswire)
07:00AM	Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass (GlobeNewswire)
06:41AM	Sanofi and Regeneron report results from two Phase III trials of COPD treatment (Pharmaceutical Technology)
05:11AM	Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline (The Wall Street Journal)
04:45AM	Stock Market Today: Dow Futures Fall; China Says U.S. Has 'Seriously Undermined' Trade Truce (The Wall Street Journal)
May-31-25 08:04AM	Libtayo (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing (GlobeNewswire)
May-30-25 06:22PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research) -19.01%
05:12PM	S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet (Investopedia)
04:23PM	Regeneron stock sinks over trial data for smoker's lungs drug (Yahoo Finance Video)
12:46PM	Why Regeneron (REGN) Shares Are Falling Today (StockStory)
12:07PM	Unity upgrade, UiPath earnings, Regeneron drug trial results (Yahoo Finance Video)
11:59AM	Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More (Investopedia)
10:31AM	COPD Drug Developed by Regeneron, Sanofi Fails Key Test (Investopedia)
10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks)
10:19AM	Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies (Zacks)
10:11AM	Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. (Barrons.com)
09:01AM	Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure (Investor's Business Daily)
08:30AM	Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data (Benzinga)
06:37AM	Regeneron shares slide on mixed trial data for smoker's lung drug (Reuters)
06:34AM	Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials (The Wall Street Journal)
04:25AM	Sanofi, Regeneron shares nosedive after mixed Itepekimab results (Investing.com)
03:19AM	Sanofi, Regenerons Itepekimab Delivers Mixed Results in Late-Stage Trials (The Wall Street Journal)
01:00AM	Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials (GlobeNewswire)
May-29-25 03:35PM	Heart Disease Could Be a Goner When These New Drugs Arrive (Barrons.com)
10:04AM	Regeneron to deploy Telesis Bios Gibson SOLA at R&D facilities (Pharmaceutical Technology)
05:30AM	The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. (Motley Fool)
12:32AM	Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency (Insider Monkey)
May-24-25 05:31AM	Does the 23andMe Acquisition Make Regeneron a Buy Now? (Motley Fool)
May-23-25 05:10PM	Regeneron announces initial results from two cohorts of LINKER-MM2 trial (TipRanks)
04:09PM	Regeneron Initial Data on Multiple Myeloma Drug Encouraging (Zacks)
04:02PM	Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication (Zacks)
10:01AM	Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases (Zacks)
06:19AM	FDA Approves GSK's Nucala for Expanded Use in COPD (Zacks)
03:00AM	Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them. (Barrons.com)
May-22-25 05:00PM	Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
10:18AM	Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A "Very Smart Deal," Says Jim Cramer (Insider Monkey)
May-21-25 10:51AM	Viz.ai, Sanofi and Regeneron to link for COPD management (Pharmaceutical Technology)
05:45AM	Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal (Benzinga)
May-20-25 05:06PM	S&P 500 Gains and Losses Today: FICO Stock Falls as Federal Housing Official Questions Pricing (Investopedia)
12:12PM	ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care (Pharmaceutical Technology)
11:35AM	Evercore says 23andMe buyout removes downside case for OraSure (TipRanks)
09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks)
07:30AM	Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD) (Business Wire)
06:48AM	Jamie Dimons Tariffs Warning Should Have Rocked Markets. Why Hes Being Ignored. (Barrons.com)
04:59AM	Company News for May 20, 2025 (Zacks)
May-19-25 04:42PM	Regeneron to acquire bankrupt genetic tester 23andMe (Yahoo Finance Video)
03:29PM	Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal (Benzinga)
02:30PM	Squawk Pod: Walter Isaacson & Business Roundtable CEO Josh Bolten - 05/19/25 Audio Only (CNBC TV)
01:52PM	Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million (The Wall Street Journal)
12:42PM	Regeneron Buys 23andMe in Bankruptcy Auction (Investopedia)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SING GEORGE L	Director	Dec 31 '24	Option Exercise	413.33	3,338	1,379,696	29,610	Jan 03 04:02 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Nov 05 04:23 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Sale	844.61	1,000	844,610	12,931	Nov 05 04:23 PM
MARION E MCCOURT	Officer	Nov 01 '24	Proposed Sale	844.61	1,000	844,610		Nov 01 04:38 PM
RYAN ARTHUR F	Director	Oct 01 '24	Sale	1048.78	100	104,878	17,582	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Sale	1054.06	1,000	1,054,060	12,931	Oct 03 04:02 PM
MARION E MCCOURT	Officer	Oct 01 '24	Proposed Sale	1054.06	1,000	1,054,060		Oct 01 04:13 PM
McCourt Marion	EVP Commercial	Sep 03 '24	Option Exercise	381.40	1,000	381,400	13,931	Sep 05 04:01 PM
McCourt Marion	EVP Commercial	Sep 03 '24	Sale	1178.73	1,000	1,178,730	12,931	Sep 05 04:01 PM
RYAN ARTHUR F	Director	Sep 03 '24	Sale	1178.68	100	117,868	17,682	Sep 05 04:01 PM
MARION E MCCOURT	Officer	Sep 03 '24	Proposed Sale	1178.73	1,000	1,178,730		Sep 03 04:04 PM
Fenimore Christopher R.	SVP Finance & CFO	Aug 28 '24	Sale	1205.33	5,680	6,846,262	0	Aug 29 04:27 PM
Christopher Fenimore	Officer	Aug 28 '24	Proposed Sale	1205.21	5,680	6,845,565		Aug 28 04:35 PM
Bassler Bonnie L	Director	Aug 15 '24	Option Exercise	371.40	756	280,778	2,138	Aug 19 04:02 PM
Bassler Bonnie L	Director	Aug 15 '24	Sale	1170.00	756	884,520	1,382	Aug 19 04:02 PM
POON CHRISTINE A	Director	Aug 15 '24	Option Exercise	413.33	10,838	4,479,671	13,010	Aug 19 04:01 PM
POON CHRISTINE A	Director	Aug 15 '24	Sale	1158.17	10,838	12,552,284	2,172	Aug 19 04:01 PM
Christine Poon	Director	Aug 15 '24	Proposed Sale	1156.86	10,838	12,538,049		Aug 15 05:55 PM
MURPHY ANDREW J	EVP Research	Aug 13 '24	Option Exercise	399.66	20,000	7,993,200	68,306	Aug 15 04:01 PM
MURPHY ANDREW J	EVP Research	Aug 14 '24	Sale	1153.15	6,363	7,337,505	48,306	Aug 15 04:01 PM
Bassler Bonnie L	Director	Aug 15 '24	Proposed Sale	1170.00	756	884,520		Aug 15 11:45 AM
MURPHY ANDREW J	Officer	Aug 14 '24	Proposed Sale	1152.27	6,363	7,331,894		Aug 14 04:08 PM
STAHL NEIL	EVP Research and Development	Aug 08 '24	Sale	1084.54	5,197	5,636,346	50,999	Aug 12 04:05 PM
Neil Stahl	Officer	Aug 08 '24	Proposed Sale	1084.46	5,197	5,635,926		Aug 08 04:53 PM
Pitofsky Jason	VP Controller	Aug 07 '24	Option Exercise	372.46	487	181,388	4,691	Aug 07 04:40 PM
Pitofsky Jason	VP Controller	Aug 07 '24	Sale	1070.00	487	521,090	4,204	Aug 07 04:40 PM
Jason Pitofsky	Officer	Aug 07 '24	Proposed Sale	1069.75	487	520,970		Aug 07 04:33 PM
STAHL NEIL	EVP Research and Development	Aug 02 '24	Option Exercise	555.67	23,638	13,134,927	74,637	Aug 06 04:03 PM
Bassler Bonnie L	Director	Aug 02 '24	Option Exercise	371.40	756	280,778	2,138	Aug 05 04:05 PM
Bassler Bonnie L	Director	Aug 02 '24	Sale	1115.00	756	842,940	1,382	Aug 05 04:05 PM
McCourt Marion	EVP Commercial	Aug 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Aug 05 04:04 PM
McCourt Marion	EVP Commercial	Aug 01 '24	Sale	1060.86	1,137	1,206,198	12,931	Aug 05 04:04 PM
RYAN ARTHUR F	Director	Aug 01 '24	Sale	1100.03	1	1,100	17,782	Aug 05 04:01 PM
RYAN ARTHUR F	Director	Aug 01 '24	Sale	1085.53	99	107,467	17,783	Aug 05 04:01 PM
Bassler Bonnie L	Director	Aug 02 '24	Proposed Sale	1115.00	756	842,940		Aug 02 10:43 AM
MARION E MCCOURT	Officer	Aug 01 '24	Proposed Sale	1060.86	1,137	1,206,198		Aug 01 04:18 PM
Arthur F. Ryan	Director	Aug 01 '24	Proposed Sale	1079.19	300	323,757		Aug 01 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jul 11 '24	Sale	1088.95	1,866	2,031,981	37,937	Jul 12 04:00 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Jul 02 04:01 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Sale	1047.11	1,137	1,190,564	12,931	Jul 02 04:01 PM
RYAN ARTHUR F	Director	Jul 01 '24	Sale	1059.24	100	105,924	17,882	Jul 02 04:01 PM
Bassler Bonnie L	Director	Jun 24 '24	Option Exercise	371.40	756	280,778	2,138	Jun 25 04:41 PM
Bassler Bonnie L	Director	Jun 24 '24	Sale	1062.00	756	802,872	1,382	Jun 25 04:41 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jun 24 '24	Option Exercise	555.67	14,450	8,029,431	50,887	Jun 25 04:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience